Back to Journals » Infection and Drug Resistance » Call For Papers

Infection and Drug Resistance


The following Article Collection/ Thematic Series is currently open for submissions:

Respiratory Syncytial Virus (RSV): progress, challenges and outcomes

Dove Medical Press is pleased to invite you to submit your research to an upcoming Thematic Series on "Respiratory Syncytial Virus (RSV): progress, challenges and outcomes", edited by Editor-in-Chief Professor Suresh Antony in Infection and Drug Resistance.

Upon submission, please use the promo code PUYAG for 20% off the advertised article processing charge and indicate that your manuscript will be considered for the Thematic Series of "Respiratory Syncytial Virus (RSV): progress, challenges and outcomes". The deadline for manuscripts is the 1st of September 2022.

For any enquiries, please email Darcy Hodge, Commissioning Editor at [email protected]

About the Thematic Series

Respiratory Syncytial Virus (RSV) can lead to symptoms akin to the common cold or winter flu, runny nose, cough, fever and so on. While the body can conquer the infection by itself, there are serious implications to being infected with RSV, as it is a common cause of pneumonia or bronchitis in infants aged under one year of age. Vulnerable patients, including the elderly and immunocompromised, may also be put at risk of further harm from an RSV infection.

During the COVID-19 pandemic, a dip in RSV infections was noted in the United States, meaning the pandemic could have influenced the transmission of RSV during this period. This Thematic Series will consider how infection rates prior to the pandemic differ from to those from 2020 onwards. Questions we’ll be asking include the factors leading to these changes, how does COVID-19 infection affect RSV, or mortality rates. The body’s immunity response will also have a vital role in this Thematic Series, to provide further understanding on where the dangers of RSV lie.

Considering these topics, we hope the submissions will culminate into a fount of knowledge about RSV. This includes efforts to find successful treatments and preventions for RSV, such as antiviral drugs and vaccinations. What sort of treatment should drug developers be looking for? Do we need to take consideration of special populations? These facets of a complicated infection – such as RSV – will be accounted for in this crucial Thematic Series.

The journal is seeking original submissions and review articles on the following topics related to RSV:

• Infection rates before and since the COVID-19 pandemic
• Driving factors behind the infection changes
• Immunity cell responses to RSV and the role of antiviral inhibitors
• RSV interactions with cell receptors
• Infant mortality rates from RSV
• Pneumonia deaths originating from RSV infection
• Interaction between COVID-19 and RSV infections
• Different vaccination types currently in development (e.g., Live attenuated, mRNA, polyvalent etc.)

Submit your manuscript
https://www.dovepress.com/submit_step_1.php

View all papers in this thematic series


Call For Papers

Editor-in-Chief: Professor Suresh Antony

To see where Infection and Drug Resistance is indexed online view the Journal Metrics.

What is the advantage to you of publishing in Infection and Drug Resistance?

  • It is an open access journal which means that your paper is available to anyone in the world to download for free directly from the Dove website.
  • Although Infection and Drug Resistance receives many papers, unlike most traditional journals, your paper will not be rejected due to lack of space. We are an electronic journal and there are no limits on the number or size of the papers we can publish.
  • The time from submission to a decision being made on a paper can, in many journals, take some months and this is very frustrating for authors. Infection and Drug Resistance has a quicker turnaround time than this. Generally peer review is complete within 3-4 weeks and the editor’s decision within 2-14 days of this. It is therefore very rare to have to wait more than 6 weeks for first editorial decision.
  • Many authors have found that our peer reviewer’s comments substantially add to their final papers.

To recover our editorial and production costs and continue to provide our content at no cost to readers we charge authors or their institution a publication processing fee.

PubMed Central
Infection and Drug Resistance is indexed on PubMed Central (title abbreviation: Infect Drug Resist). All published papers in this journal are submitted to PubMed for indexing straight away.

Become a Favored Author and receive real benefits
If you haven't already joined the Dove Press Favored Author Program I would encourage you to do so. Why? To receive real benefits like fast-tracking and a personal co-ordinator for your paper, as well as a discount on the publication processing fee.
Click here to go through to the Favored Author signup page, you'll just need to supply the working title of your next paper and when you intend to submit by.

Yours sincerely
Professor Suresh Antony
Editor-in-Chief
Infection and Drug Resistance

Email: Editor-in-Chief